• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Inspire Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    6/13/25 6:19:04 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care
    Get the next $INSP alert in real time by email
    insp-20250613
    0001609550False00016095502025-06-132025-06-13


    SECURITIES AND EXCHANGE
    Washington, D.C. 20549
    _________________________
    FORM 8-K
    _________________________
    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): June 13, 2025
    _________________________
    INSPIRE MEDICAL SYSTEMS, INC.
    (Exact name of registrant as specified in its charter)
    _________________________
    Delaware001-3846826-1377674
    (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
    5500 Wayzata Blvd., Suite 1600
    Golden Valley, Minnesota 55416
    (Address of principal executive offices) (Zip Code)

    (844) 672-4357
    (Registrant’s telephone number, including area code)

    N/A
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 par value per shareINSPNew York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company     ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
    period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 7.01. Regulation FD Disclosure.
    In June 2025, the Company will be participating in various meetings with investors and analysts, and a copy of the Company’s presentation materials being used at these meetings is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. These presentation materials are also available on the Investor Relations page of the Company’s website at https://investors.inspiresleep.com.

    The information in Item 7.01 of this Current Report on Form 8-K and the presentation attached as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01.    Financial Statements and Exhibits.
    (d) Exhibits

    Exhibit No.Description
    99.1
    Inspire Medical Systems, Inc. Presentation dated June 13, 2025.
    104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    INSPIRE MEDICAL SYSTEMS, INC.
    Date:June 13, 2025By:/s/ Richard J. Buchholz
    Richard J. Buchholz
    Chief Financial Officer

    3
    Get the next $INSP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INSP

    DatePrice TargetRatingAnalyst
    8/5/2025$125.00Buy → Hold
    Truist
    8/5/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    8/5/2025$110.00Overweight → Neutral
    Analyst
    11/20/2024$220.00 → $255.00Neutral → Buy
    BofA Securities
    5/8/2024$265.00 → $225.00Buy → Neutral
    BofA Securities
    4/19/2024$285.00Outperform
    RBC Capital Mkts
    3/19/2024$250.00Overweight
    Morgan Stanley
    2/6/2024$278.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $INSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ellis Gary Lee was granted 221 shares, increasing direct ownership by 4% to 6,082 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    7/16/25 4:08:06 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Director Tansey Casey M was granted 133 shares, increasing direct ownership by 0.61% to 22,014 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    7/16/25 4:07:24 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Director Broader Shelley G was granted 148 shares, increasing direct ownership by 4% to 4,122 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    7/16/25 4:06:08 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Inspire Medical Systems Inc.

    SCHEDULE 13G - Inspire Medical Systems, Inc. (0001609550) (Subject)

    8/14/25 4:30:03 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)

    8/11/25 4:16:24 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Inspire Medical Systems Inc.

    10-Q - Inspire Medical Systems, Inc. (0001609550) (Filer)

    8/4/25 4:16:57 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Inspire Medical Systems downgraded by Truist with a new price target

    Truist downgraded Inspire Medical Systems from Buy to Hold and set a new price target of $125.00

    8/5/25 8:00:09 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded Inspire Medical Systems from Overweight to Sector Weight

    8/5/25 7:09:41 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems downgraded by Analyst with a new price target

    Analyst downgraded Inspire Medical Systems from Overweight to Neutral and set a new price target of $110.00

    8/5/25 7:09:41 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sparks Charisse Y bought $15,350 worth of shares (100 units at $153.50), increasing direct ownership by 11% to 998 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    1/24/24 4:32:03 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program

    MINNEAPOLIS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that its Board of Directors has authorized the repurchase of up to $200 million of the company's outstanding shares of common stock. "I am pleased to announce our intention to purchase up to $200 million of Inspire common stock," said Tim Herbert, Chairman and Chief Executive Officer. "During the second quarter, we initiated the full U.S. launch of Inspire V, our next-generation neurostimula

    8/11/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook

    MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2025. Recent Business Highlights Generated revenue of $217.1 million in the second quarter of 2025, an 11% increase over the same quarter last yearAchieved gross margin of 84.0% in the second quarter of 2025Net loss was $3.6 million in the second quarter of 2025. Adjusted net income was $13.3 millionLoss per share was $0.12 in the second quarter of

    8/4/25 4:02:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. to Report Second Quarter 2025 Financial Results on August 4, 2025

    MINNEAPOLIS, July 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the second quarter 2025 after the close of trading on Monday, August 4. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followin

    7/7/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 21, 2023 - FDA Roundup: March 21, 2023

    For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

    3/21/23 3:12:46 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Financials

    Live finance-specific insights

    View All

    Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook

    MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2025. Recent Business Highlights Generated revenue of $217.1 million in the second quarter of 2025, an 11% increase over the same quarter last yearAchieved gross margin of 84.0% in the second quarter of 2025Net loss was $3.6 million in the second quarter of 2025. Adjusted net income was $13.3 millionLoss per share was $0.12 in the second quarter of

    8/4/25 4:02:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. to Report Second Quarter 2025 Financial Results on August 4, 2025

    MINNEAPOLIS, July 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the second quarter 2025 after the close of trading on Monday, August 4. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followin

    7/7/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook

    Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2025. Recent Business Highlights Generated revenue of $201.3 million in the first quarter of 2025, a 23% increase over the same quarter last yearAchieved gross margin of 84.7% in the first quarter of 2025Generated earnings per share of $0.10 in

    5/5/25 4:02:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    11/12/24 10:32:14 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    10/4/24 2:09:06 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Inspire Medical Systems Inc. (Amendment)

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    2/13/24 5:06:20 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Leadership Updates

    Live Leadership Updates

    View All

    Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors

    MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.   "Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, a

    4/21/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Presidio Medical™ Announces Appointment of Richard J. Buchholz to Join its Board of Directors

    Presidio Medical, Inc., a clinical stage company developing a transformational neuromodulation platform, is pleased to announce Richard J. Buchholz will join its Board of Directors. Rick is the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE:INSP), where he has played a pivotal role in driving strategic financial and operational growth for the global leader in the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. "We are excited that Rick is joining the Board of Directors of Presidio Medical at this critical time in our company's journey. His leadership and financial acumen will be instrumental in advanc

    12/5/24 12:12:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care